Susana M. Campos, MD
With 3 PARP inhibitors available for patients with recurrent ovarian cancer and in the maintenance setting, Susana Campos, MD, MPH, said that ongoing clinical trials will answer questions about where the future management of the disease is headed.
on Ovarian Cancer, Campos highlighted the success with PARP inhibitors in the relapsed and maintenance ovarian cancer settings.
OncLive: Could you highlight the key takeaways from your presentation on PARP inhibitors?
: We talked about PARP inhibitors and how they have infiltrated the world of ovarian cancer, and in many ways how they have changed the course of ovarian cancer. I spoke a bit about what some of the PARP inhibitors are in the recurrent setting as single agents—where it all started.
... to read the full story